Healio wins APEX award for Psychedelics & Alternative Therapies collection

Key takeaways:

• The APEX award was one of six total won by Healio in 2024.
• The Psychedelics & Alternative Therapies resource center is a collection of stories that focus on the use of these substances in health care.

The Healio news staff received an APEX award in the category of Writing/Topics for work on the potential role of psychedelics and alternative therapies for mental health issues and other medical conditions.

The work is housed in Healio’s Psychedelics & Alternative Therapies resource center.

“Psychedelics and alternative therapies have become increasingly relevant across the spectrum of health care,” said Healio Senior Editorial Director Nancy Hemphill, ELS, FAAO. “Our team at Healio Neurology spearheaded the creation of this resource center, but nearly all of Healio’s specialties contribute to the content, speaking to the fact that this is a burgeoning area of treatment potential.”

The APEX awards recognize publication excellence and achievement of communications effectiveness in graphic design and editorial content across 13 categories and 100 subcategories. There were more than 1,100 entries this year, of which 100 received the designation as grand award winners. Healio received a total of 6 APEX awards this year, including two grand awards.

Since its launch in 2022, the Psychedelics & Alternative Therapies collection has been home to articles ranging from the latest clinical trial results, industry insights and breaking news to in-depth features on the potential healing power of substances such as psilocybin, ketamine and lysergide, as well as cannabis and cannabis-related products, to address conditions such as anxiety, depression, PTSD, epilepsy, trauma, sleep disorders, chronic pain relief and cancer.

‘New Hope’ for psychedelic treatments

At the American Psychiatric Association Annual Meeting, recent FDA-approved groundbreaking therapeutics were lauded for their healing potential. Read more.

Ketamine as depression solution

Recent research published in JAMA Network Open found that ketamine may be more beneficial than electroconvulsive therapy for less severe types of treatment-resistant depression. Read more.

Timing crucial with psilocybin, sleep issues

Psilocybin isn’t the cure-all some may believe. At the American Headache Society Annual Scientific Meeting, researchers reported that the timing of treatment is important regarding headache and sleep rhythms. Read more.

Groundbreaking MDMA news

The FDA issued a complete response letter to Lycos Therapeutics for its new drug application regarding midomafetamine capsules for the treatment of PTSD, citing insufficient data to approve and requesting an additional phase 3 trial. Read more.